Edgewood Oncology

About

Edgewood Oncology, Inc. is a clinical-stage biotechnology company founded to deliver on the promise of BTX-A51 for patients with hematologic malignancies and genetically defined solid tumors. BTX-A51 is an investigational, first-in-class, small molecule, multi-selective kinase inhibitor of CK1α, CDK7, and CDK9 that synergistically co-targets master regulators of cancer to activate programmed cell death or apoptosis. BTX-A51 holds promise in acute myeloid leukemia and genetically defined solid tumors, which are the focus of ongoing clinical programs.